
Astronomers capture an image of a potential planet forming around star
Planets form out of the leftover gas and dust once a star has ignited, and it's believed that the forming planet or planets create a disk around the host star. While astronomers have seen this protoplanetary disk around many stars, they have never before photographed an actual planet forming within, an action that creates spiral-like structures.
While earlier observations of this star didn't reveal any object that could be orbiting it, the team that made this discovery used a different instrument that looked at it in a different wavelength.
The authors of the study, published Monday in the journal The Astrophysical Journal Letters, say they haven't yet confirmed that what they've captured is the formation of a planet or protoplanet.
"We have only one image [in] only one wavelength," said Francesco Maio, a doctoral researcher at the University of Florence, and lead author of the study. "We have three images where we don't see this object. So we need to understand the properties of these candidate protoplanets."
The object is roughly 440 light years away in a binary, or double, star system, and is believed to be twice the size of Jupiter. It orbits its host star at a distance similar to that of Neptune's distance from the sun.
'Like a cappuccino'
Maio described finding the potential planet in the disk in a uniquely Italian way.
"The disk is like a cappuccino. The planet is like a spoon in the cappuccino. And when you move the spoon inside the cappuccino, you start to form spirals," he said.
Though scientists have previously observed the spirals, Maio says this is the first time they've been able to see what is potentially causing them.
"We are not able until now to see the planet that perturbed and generated a spiral," he said. "So you already see this cappuccino with spirals, but we never see the spoons."
The discovery was made using the Very Large Telescope (VLT) and its Enhanced Resolution Imager and Spectrograph (ERIS) instrument at the European Southern Observatory (ESO) in Chile.
The disk itself was imaged by another team of astronomers using a different instrument called SPHERE (Spectro-Polarimetric High-contrast Exoplanet REsearch), which can block out the light of a star in order to see if there are any objects around it. But the previous researchers didn't find anything orbiting the star.
Still, researchers say it's promising.
"This is an interesting observation. People have been seeing these spiral structures in protoplanetary disks for a long time," said Hanno Rein, an associate professor at the University of Toronto and an exoplanet researcher who was not part of the study.
"What's usually missing is the object that is actually creating those spiral arms, or that is forming in those disks. And this team here seems to have found one strong candidate of an object that is at the base of one of those spiral arms that might be a planet forming."
2 stars, different environments
Another interesting twist to this discovery is that there is another star in the system, whose environment is very different.
The pair are collectively known as HD 135344AB. The star that this potential planet is orbiting is HD 135344B.
Both stars are roughly the same age, Maio said. Yet, the other star in the system — HD 135344A — has no protoplanetary disk.
"This is very interesting, scientifically speaking, because we don't know why two very similar stars evolved together as two different systems," Maio said.
Earlier this month, astronomers looked at the second star with ESO's VLT and SPHERE instrument and found a planet with roughly 10 times Jupiter's mass.
While that's one mystery, the question of whether or not there is a protoplanet in the disk of gas and dust from Monday's study will need further investigating, Maio said, and will likely require using other wavelengths to look.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
3 hours ago
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:


Globe and Mail
a day ago
- Globe and Mail
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patients with narcolepsy type 1 (NT1). In the Vibrance-1 study, patients were randomized to receive alixorexton (4 mg, 6 mg or 8 mg) or placebo to be taken once daily for six weeks. Data from the study showed that treatment with alixorexton across all doses led to a statistically significant, clinically meaningful and dose-dependent improvement from baseline versus placebo in wakefulness on the Maintenance of Wakefulness Test (MWT) — the study's primary endpoint. Treatment with alixorexton across all doses demonstrated statistically significant and clinically meaningful improvements from baseline in excessive daytime sleepiness versus placebo at week six on the Epworth Sleepiness Scale — a key secondary endpoint of the Vibrance-1 study. Although all three doses of alixorexton led to improvements in weekly cataplexy rates — also a key secondary endpoint of the study — only the 6 mg dose achieved statistical significance. This might have hurt investor sentiment and caused the stock to decline 8.8% yesterday. Also, treatment with once-daily alixorexton led to robust and clinically meaningful improvements in patient-reported outcomes for excessive daytime sleepiness, fatigue and cognition compared to placebo. Treatment with alixorexton across all doses was generally safe and well-tolerated. ALKS' Price Performance Shares of Alkermes have declined 7.3% so far this year compared with the industry 's decrease of 2.2%. Building on the overall success of the Vibrance-1 study, management is planning to initiate a global phase III program for alixorexton in patients with NT1. NT1 is a chronic sleep disorder causing excessive daytime sleepiness and sudden muscle weakness called cataplexy due to orexin deficiency. We note that orexin agonists like alixorexton directly target the brain's orexin system — the root cause of NT1. Unlike other available drugs that only fight sleepiness, orexin agonists may also prevent cataplexy, offering a more natural and complete treatment approach. This can make them a promising and transformative treatment in narcolepsy care. The detailed safety and efficacy data from the phase II Vibrance-1 study are expected to be presented at an upcoming scientific conference. ALKS' Other Development Activities With Alixorexton Besides NT1, alixorexton is also being studied for the treatment of narcolepsy type 2 ('NT2') and idiopathic hypersomnia ('IH'). The phase II Vibrance-2 study is evaluating the safety and efficacy of alixorexton versus placebo in adults with NT2. Enrollment in this study is expected to be completed shortly, with data from the same expected during fall. In April 2025, the company initiated the phase II Vibrance-3 study, evaluating the safety and efficacy of alixorexton in adults with idiopathic hypersomnia, a rare, chronic and neurological sleep disorder. Per management, if successfully developed and upon potential approval, alixorexton can serve an area of high unmet medical need in the treatment of NT1 and NT2 as well as IH. However, upon potential approval, alixorexton is likely to face competition from Axsome 's AXSM Sunosi (solriamfetol), which is presently marketed in the United States for the treatment of narcolepsy. Several label expansion studies on solriamfetol are also currently underway. Axsome acquired the U.S. rights for Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. AXSM began selling Sunosi in the U.S. market in May 2022. JAZZ received approval for Sunosi as a treatment for narcolepsy in 2019. Jazz's other sleep disorder drugs, Xyrem and Xywav, also hold a strong market share. ALKS' Zacks Rank & Stock to Consider Alkermes currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Arvinas ARVN, sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for Arvinas' 2025 loss per share have narrowed from $1.60 to $1.51. Loss per share estimates for 2026 have narrowed from $3.28 to $2.98 during the same period. ARVN stock has plunged 60.7% year to date. Arvinas' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report Arvinas, Inc. (ARVN): Free Stock Analysis Report


CBC
a day ago
- CBC
Astronomers capture an image of a potential planet forming around star
Astronomers believe they have caught a planet in the act of forming, something that has never before been witnessed. Planets form out of the leftover gas and dust once a star has ignited, and it's believed that the forming planet or planets create a disk around the host star. While astronomers have seen this protoplanetary disk around many stars, they have never before photographed an actual planet forming within, an action that creates spiral-like structures. While earlier observations of this star didn't reveal any object that could be orbiting it, the team that made this discovery used a different instrument that looked at it in a different wavelength. The authors of the study, published Monday in the journal The Astrophysical Journal Letters, say they haven't yet confirmed that what they've captured is the formation of a planet or protoplanet. "We have only one image [in] only one wavelength," said Francesco Maio, a doctoral researcher at the University of Florence, and lead author of the study. "We have three images where we don't see this object. So we need to understand the properties of these candidate protoplanets." The object is roughly 440 light years away in a binary, or double, star system, and is believed to be twice the size of Jupiter. It orbits its host star at a distance similar to that of Neptune's distance from the sun. 'Like a cappuccino' Maio described finding the potential planet in the disk in a uniquely Italian way. "The disk is like a cappuccino. The planet is like a spoon in the cappuccino. And when you move the spoon inside the cappuccino, you start to form spirals," he said. Though scientists have previously observed the spirals, Maio says this is the first time they've been able to see what is potentially causing them. "We are not able until now to see the planet that perturbed and generated a spiral," he said. "So you already see this cappuccino with spirals, but we never see the spoons." The discovery was made using the Very Large Telescope (VLT) and its Enhanced Resolution Imager and Spectrograph (ERIS) instrument at the European Southern Observatory (ESO) in Chile. The disk itself was imaged by another team of astronomers using a different instrument called SPHERE (Spectro-Polarimetric High-contrast Exoplanet REsearch), which can block out the light of a star in order to see if there are any objects around it. But the previous researchers didn't find anything orbiting the star. Still, researchers say it's promising. "This is an interesting observation. People have been seeing these spiral structures in protoplanetary disks for a long time," said Hanno Rein, an associate professor at the University of Toronto and an exoplanet researcher who was not part of the study. "What's usually missing is the object that is actually creating those spiral arms, or that is forming in those disks. And this team here seems to have found one strong candidate of an object that is at the base of one of those spiral arms that might be a planet forming." 2 stars, different environments Another interesting twist to this discovery is that there is another star in the system, whose environment is very different. The pair are collectively known as HD 135344AB. The star that this potential planet is orbiting is HD 135344B. Both stars are roughly the same age, Maio said. Yet, the other star in the system — HD 135344A — has no protoplanetary disk. "This is very interesting, scientifically speaking, because we don't know why two very similar stars evolved together as two different systems," Maio said. Earlier this month, astronomers looked at the second star with ESO's VLT and SPHERE instrument and found a planet with roughly 10 times Jupiter's mass. While that's one mystery, the question of whether or not there is a protoplanet in the disk of gas and dust from Monday's study will need further investigating, Maio said, and will likely require using other wavelengths to look.